ITMI20100840A1 - TOPICAL PHYTOTHERAPY COMPOSITIONS - Google Patents
TOPICAL PHYTOTHERAPY COMPOSITIONS Download PDFInfo
- Publication number
- ITMI20100840A1 ITMI20100840A1 IT000840A ITMI20100840A ITMI20100840A1 IT MI20100840 A1 ITMI20100840 A1 IT MI20100840A1 IT 000840 A IT000840 A IT 000840A IT MI20100840 A ITMI20100840 A IT MI20100840A IT MI20100840 A1 ITMI20100840 A1 IT MI20100840A1
- Authority
- IT
- Italy
- Prior art keywords
- oil
- helichrysum
- compositions
- compositions according
- fat
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims description 32
- 230000000699 topical effect Effects 0.000 title claims description 7
- 238000009160 phytotherapy Methods 0.000 title description 2
- 239000003921 oil Substances 0.000 claims description 20
- 239000000341 volatile oil Substances 0.000 claims description 15
- 239000000284 extract Substances 0.000 claims description 13
- 244000125300 Argania sideroxylon Species 0.000 claims description 12
- 239000010497 wheat germ oil Substances 0.000 claims description 12
- 235000016108 Argania sideroxylon Nutrition 0.000 claims description 11
- 235000009024 Ceanothus sanguineus Nutrition 0.000 claims description 11
- 235000015459 Lycium barbarum Nutrition 0.000 claims description 11
- 239000010653 helichrysum oil Substances 0.000 claims description 11
- 235000013399 edible fruits Nutrition 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 201000010099 disease Diseases 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 230000002538 fungal effect Effects 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 230000001681 protective effect Effects 0.000 claims description 3
- 230000008929 regeneration Effects 0.000 claims description 3
- 238000011069 regeneration method Methods 0.000 claims description 3
- 230000003612 virological effect Effects 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 230000002757 inflammatory effect Effects 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 240000003553 Leptospermum scoparium Species 0.000 claims 4
- 244000308760 Helichrysum petiolatum Species 0.000 claims 2
- 239000007764 o/w emulsion Substances 0.000 claims 1
- 239000007762 w/o emulsion Substances 0.000 claims 1
- 235000019198 oils Nutrition 0.000 description 16
- 241000366182 Melaleuca alternifolia Species 0.000 description 15
- 230000003078 antioxidant effect Effects 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 244000098338 Triticum aestivum Species 0.000 description 6
- 230000003110 anti-inflammatory effect Effects 0.000 description 6
- 241000608894 Helichrysum Species 0.000 description 5
- 239000003974 emollient agent Substances 0.000 description 5
- -1 moisturizing Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 230000000843 anti-fungal effect Effects 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 3
- 235000018625 Helichrysum angustifolium Nutrition 0.000 description 3
- 244000292571 Helichrysum italicum Species 0.000 description 3
- 235000013530 Helichrysum italicum Nutrition 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 230000004075 alteration Effects 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 229940121375 antifungal agent Drugs 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000003647 oxidation Effects 0.000 description 3
- 238000007254 oxidation reaction Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 206010017533 Fungal infection Diseases 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 241000378467 Melaleuca Species 0.000 description 2
- 208000031888 Mycoses Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 239000004288 Sodium dehydroacetate Substances 0.000 description 2
- 239000010478 argan oil Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 229920002770 condensed tannin Polymers 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229940087305 limonene Drugs 0.000 description 2
- 235000001510 limonene Nutrition 0.000 description 2
- 150000002632 lipids Chemical group 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 229940079839 sodium dehydroacetate Drugs 0.000 description 2
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 2
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000010677 tea tree oil Substances 0.000 description 2
- 229940111630 tea tree oil Drugs 0.000 description 2
- QAIPRVGONGVQAS-DUXPYHPUSA-N trans-caffeic acid Chemical compound OC(=O)\C=C\C1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-DUXPYHPUSA-N 0.000 description 2
- ACEAELOMUCBPJP-UHFFFAOYSA-N (E)-3,4,5-trihydroxycinnamic acid Natural products OC(=O)C=CC1=CC(O)=C(O)C(O)=C1 ACEAELOMUCBPJP-UHFFFAOYSA-N 0.000 description 1
- WRYLYDPHFGVWKC-JTQLQIEISA-N (R)-(-)-p-Menth-1-en-4-ol Natural products CC(C)[C@@]1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-JTQLQIEISA-N 0.000 description 1
- PDNLXUROKBBMBE-BYOHNYAZSA-N (Z)-octadec-9-enoic acid (3R,4S,5R,6R)-3,4,5,6,7-pentahydroxyheptan-2-one Chemical compound CC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O PDNLXUROKBBMBE-BYOHNYAZSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- OARDBPIZDHVTCK-UHFFFAOYSA-N 2-butyloctanoic acid Chemical compound CCCCCCC(C(O)=O)CCCC OARDBPIZDHVTCK-UHFFFAOYSA-N 0.000 description 1
- WRYLYDPHFGVWKC-UHFFFAOYSA-N 4-terpineol Chemical compound CC(C)C1(O)CCC(C)=CC1 WRYLYDPHFGVWKC-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000035890 Helichrysum arenarium Species 0.000 description 1
- 241000036257 Helichrysum stoechas Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- GLZPCOQZEFWAFX-JXMROGBWSA-N Nerol Natural products CC(C)=CCC\C(C)=C\CO GLZPCOQZEFWAFX-JXMROGBWSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000002725 Olea europaea Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003501 anti-edematous effect Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229940074360 caffeic acid Drugs 0.000 description 1
- 235000004883 caffeic acid Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- QAIPRVGONGVQAS-UHFFFAOYSA-N cis-caffeic acid Natural products OC(=O)C=CC1=CC=C(O)C(O)=C1 QAIPRVGONGVQAS-UHFFFAOYSA-N 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- PMMXXYHTOMKOAZ-UHFFFAOYSA-N hexadecyl 7-methyloctanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCC(C)C PMMXXYHTOMKOAZ-UHFFFAOYSA-N 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003960 inflammatory cascade Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- CYDVXGDTOKENRK-UHFFFAOYSA-L magnesium;dodecanoic acid;sulfate Chemical compound [Mg+2].[O-]S([O-])(=O)=O.CCCCCCCCCCCC(O)=O CYDVXGDTOKENRK-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 229940044591 methyl glucose dioleate Drugs 0.000 description 1
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 108700004121 sarkosyl Proteins 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 1
- 229940045885 sodium lauroyl sarcosinate Drugs 0.000 description 1
- 229960004025 sodium salicylate Drugs 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003595 thromboxanes Chemical class 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/61—Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Botany (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
“COMPOSIZIONI TOPICHE FITOTERAPICHE†⠀ œTOPICAL PHYTOTHERAPY COMPOSITIONSâ €
Campo dell’invenzione Field of invention
La presente invenzione à ̈ relativa a composizioni topiche comprendenti olio essenziale di melaleuca, olio di germe di grano, estratto liposolubile o olio di elicriso, ed eventualmente inoltre olio di Argania Spinosa, ad attività antiinfiammatoria, cosmetica, idratante, emolliente, riparativa, ristrutturante, antibatterica, antimicotica e antivirale. The present invention relates to topical compositions comprising essential oil of tea tree, wheat germ oil, fat-soluble extract or helichrysum oil, and possibly also Argania Spinosa oil, with anti-inflammatory, cosmetic, moisturizing, emollient, reparative, restructuring, antibacterial, antifungal and antiviral.
Stato dell’arte State of the art
L’organismo reagisce alle lesioni tessutali dovute ad agenti biologici (microrganismi, virus), chimici, fisico-meccanici (traumi, radiazioni) o a patologie (ad esempio dermatiti) tramite il processo infiammatorio e i mediatori chimici dell’infiammazione (istamina, leucotrieni, prostaglandine, trombossani, interleuchine, ecc.); la difesa dell’organismo comporta diversi fenomeni, soprattutto a livello vascolare, che rendono inefficaci i fattori nocivi e permettono la riparazione dei danni subiti dai tessuti. The organism reacts to tissue lesions due to biological (microorganisms, viruses), chemical, physical-mechanical (trauma, radiation) or pathologies (for example dermatitis) through the inflammatory process and the chemical mediators of inflammation (histamine, leukotrienes) , prostaglandins, thromboxanes, interleukins, etc.); the defense of the organism involves various phenomena, especially at the vascular level, which render the harmful factors ineffective and allow the repair of the damage suffered by the tissues.
L’olio essenziale di melaleuca à ̈ impiegato da molto tempo nella terapia topica di infezioni batteriche, micotiche e virali; generalmente viene utilizzato il fitocomplesso in quanto in esso sono contenuti diversi principi attivi che con la loro azione sinergica contribuiscono all’attività batteriostatica, antimicotica e antivirale. Tea tree essential oil has been used for a long time in the topical therapy of bacterial, fungal and viral infections; the phytocomplex is generally used as it contains various active ingredients which, with their synergistic action, contribute to bacteriostatic, antifungal and antiviral activity.
L’olio di germe di grano, ricco in tocoferolo, à ̈ noto per le sue proprietà antiossidanti ed emollienti, importanti nella fase di riepitelizzazione. Wheat germ oil, rich in tocopherol, is known for its antioxidant and emollient properties, which are important in the re-epithelialization phase.
L’elicriso à ̈ impiegato da moltissimi anni come antinfiammatorio e antinfettivo. Helichrysum has been used for many years as an anti-inflammatory and anti-infective.
L’Argan (Argania Spinosa) in olio ha proprietà antiossidanti e ristrutturanti. Argan (Argania Spinosa) in oil has antioxidant and restructuring properties.
Descrizione dell’invenzione Description of the invention
Si à ̈ ora trovato che l’associazione di olio essenziale di melaleuca, olio di germe di grano, estratto liposolubile o olio di elicriso, ed eventualmente inoltre olio di Argania Spinosa, esercita un’attività antiinfiammatoria, cosmetica, idratante, emolliente, riparativa, ristrutturante, antibatterica, antimicotica e antivirale estremamente potente, e una spiccata azione antiossidante intra- ed extracellulare. It has now been found that the association of tea tree essential oil, wheat germ oil, fat-soluble extract or helichrysum oil, and possibly also Argania Spinosa oil, exerts an anti-inflammatory, cosmetic, moisturizing, emollient, repairing, restructuring, antibacterial, antifungal and antiviral extremely powerful, and a strong intra- and extracellular antioxidant action.
Pertanto la presente invenzione à ̈ relativa a composizioni comprendenti: a) olio essenziale di melaleuca (Melaleuca alternifolia), Therefore the present invention relates to compositions comprising: a) essential oil of tea tree (Melaleuca alternifolia),
b) olio di germe di grano (Triticum vulgare), e b) wheat germ oil (Triticum vulgare), e
c) estratto liposolubile o olio di elicriso (ovvero Helichrysum italicum o Helichrysum arenarium o Helichrysum stoechas), c) fat-soluble extract or helichrysum oil (i.e. Helichrysum italicum or Helichrysum arenarium or Helichrysum stoechas),
ed inoltre eventualmente d) olio di Argania Spinosa (olio di Argan). and also possibly d) Argania Spinosa oil (Argan oil).
Secondo un aspetto dell’invenzione, tali composizioni possono essere utilizzate per trattare affezioni dermatologiche di origine infiammatoria, batterica, micotica o virale, per favorire le attività protettive e il processo di rigenerazione cellulare a livello cutaneo. According to an aspect of the invention, these compositions can be used to treat dermatological diseases of inflammatory, bacterial, fungal or viral origin, to favor the protective activities and the cell regeneration process at the cutaneous level.
Il meccanismo d’azione delle composizioni dell’invenzione va considerato come un sistema che agisce a più livelli sul processo infiammatorio. Una prima azione avviene nella prima fase dell’infiammazione, contrastando la produzione di radicali liberi, rallentando così il processo infiammatorio; il secondo livello à ̈ rappresentato dall’azione diretta sui microrganismi, con l’alterazione della membrana; un terzo livello à ̈ l’azione durante la fase riparativa, stimolando la produzione di collagene ed elastina. Va sottolineato che, in considerazione dei risultati ottenuti con le composizioni dell’invenzione, superiori alla semplice sommatoria delle azioni esercitate dai singoli componenti attivi, si può ipotizzare, senza tuttavia essere legati a tale ipotesi, che i tre componenti attivi delle composizioni dell’invenzione agiscano attraverso un meccanismo di sinergia reciproca. Si à ̈ pertanto trovato che la particolare associazione di olio di melaleuca, olio di germe di grano, estratto liposolubile o olio di elicriso ed eventualmente olio di Argania Spinosa dell’invenzione sia in grado di potenziare le proprietà antinfiammatorie, antibatteriche e antimicotiche della melaleuca stessa e nello stesso tempo di favorire le attività protettive e il processo di rigenerazione cellulare e di ristrutturazione dei tessuti. The mechanism of action of the compositions of the invention must be considered as a system that acts on several levels on the inflammatory process. A first action occurs in the first phase of inflammation, counteracting the production of free radicals, thus slowing down the inflammatory process; the second level is represented by the direct action on microorganisms, with the alteration of the membrane; a third level is the action during the reparative phase, stimulating the production of collagen and elastin. It should be emphasized that, in consideration of the results obtained with the compositions of the invention, superior to the simple sum of the actions exercised by the individual active components, it can be hypothesized, without however being linked to this hypothesis, that the three active components of the compositions of the ™ invention act through a reciprocal synergy mechanism. It has therefore been found that the particular association of tea tree oil, wheat germ oil, fat-soluble extract or helichrysum oil and possibly Argania Spinosa oil of the invention is able to enhance the anti-inflammatory, antibacterial and antifungal properties of the tea tree. itself and at the same time to promote protective activities and the process of cellular regeneration and tissue restructuring.
L’olio di germe di grano, grazie alla sua azione emolliente, idratante e antiossidante, agisce in sinergia con il fitocomplesso dell’olio essenziale di Melaleuca alternifolia, l’estratto liposolubile o olio di elicriso e l’olio di Argania Spinosa a loro volta esaltano e potenziano l’azione della Melaleuca alternifolia in quanto hanno parte attiva nel processo infiammatorio e sul trofismo della cute. Wheat germ oil, thanks to its emollient, moisturizing and antioxidant action, acts in synergy with the phytocomplex of Melaleuca alternifolia essential oil, fat-soluble extract or helichrysum oil and Argan oil Spinosa in turn enhance and enhance the action of Melaleuca alternifolia as they play an active part in the inflammatory process and on the trophism of the skin.
Secondo un aspetto preferito della presente invenzione, si utilizzeranno come componenti attivi olio essenziale di Melaluca alternifolia al 2%, olio di Triticum vulgare dal 2% al 5%, estratto liposolubile o olio di elicriso al 5% ed eventualmente Argania Spinosa (frutto) olio al 3%. According to a preferred aspect of the present invention, essential oil of Melaluca alternifolia at 2%, Triticum vulgare oil from 2% to 5%, fat-soluble extract or helichrysum oil at 5% and possibly Argania Spinosa (fruit) oil will be used as active components. at 3%.
Secondo un aspetto particolarmente preferito, tali componenti potranno essere presenti nelle composizioni dell’invenzione entro i seguenti intervalli percentuali preferiti, dove tali percentuali si intendono sul totale della composizione: According to a particularly preferred aspect, such components may be present in the compositions of the invention within the following preferred percentage ranges, where these percentages are intended on the total composition:
a) olio essenziale di Melaluca alternifolia: da 1,5% a 2,5%, a) essential oil of Melaluca alternifolia: from 1.5% to 2.5%,
b) olio di Triticum vulgare: da 1,5% a 5%, b) Triticum vulgare oil: from 1.5% to 5%,
c) estratto liposolubile di elicriso: da 1,5% a 6%, c) fat-soluble extract of helichrysum: from 1.5% to 6%,
oppure olio di elicriso: da 4,5% a 6%, or helichrysum oil: from 4.5% to 6%,
d) olio di frutto di Argania Spinosa: da 3% a 6%. d) Argania Spinosa fruit oil: from 3% to 6%.
Le composizioni dell’invenzione si sono dimostrate efficaci nel trattamento di diverse affezioni dermatologiche, grazie alla loro azione antiinfiammatoria, cosmetica, idratante, emolliente, ripartiva e ristrutturante della pelle e potranno essere utilizzate in tutte quelle situazioni in cui sono presenti infezioni batteriche/micotiche/virali e in cui à ̈ necessario ripristinare l’equilibrio fisiologico a livello della barriera cutanea. The compositions of the invention have proved effective in the treatment of various dermatological diseases, thanks to their anti-inflammatory, cosmetic, moisturizing, emollient, restoring and restructuring action on the skin and can be used in all those situations in which bacterial / fungal infections are present. / viral and in which it is necessary to restore the physiological balance at the level of the skin barrier.
L’olio essenziale di Melaleuca alternifolia, che può essere ottenuto per distillazione in corrente di vapore delle foglie fresche, contiene una elevata concentrazione di terpinene-4-olo (>36%), considerato il componente attivo principale, e una bassa concentrazione di 1,8 cineolo (<4,5%), che a concentrazioni elevate può essere irritante. L’olio, in forma stabilizzata e rispondente agli standard indicati in diverse Farmacopee (ad esempio British Pharmaceutical Codex 1949 p. 597-578; Martindale; The Extra Pharmacopoeia 28° ed, 1982 p. 678), la cui composizione à ̈ riportata in J. Agric., Food Chem. 1989, 37, 1330, à ̈ attivo contro diversi batteri e funghi, à ̈ impiegato in applicazioni topiche nel trattamento di diverse infezioni dermatologiche; alla concentrazione del 2% il suo impiego à ̈ considerato sicuro, con un basso rischio di irritazione per la cute; gli eventi avversi osservati sono occasionali, l’olio essenziale di melaleuca à ̈ irritante solo a dosi elevate o se non à ̈ conservato correttamente; in questo caso si sviluppano reazioni allergiche dovute ai prodotti di ossidazione. L’olio essenziale di Melaleuca alternifolia si à ̈ dimostrato efficace in particolare contro la Candida, nel trattamento della dermatite seborroica, dell’acne, in presenza di psoriasi o herpes. The essential oil of Melaleuca alternifolia, which can be obtained by steam distillation of fresh leaves, contains a high concentration of terpinene-4-ol (> 36%), considered the main active component, and a low concentration of 1.8 cineole (<4.5%), which at high concentrations can be irritating. The oil, in stabilized form and meeting the standards indicated in various Pharmacopoeias (for example British Pharmaceutical Codex 1949 p. 597-578; Martindale; The Extra Pharmacopoeia 28 ° ed, 1982 p. 678), whose composition is reported in J. Agric., Food Chem. 1989, 37, 1330, is active against various bacteria and fungi, is used in topical applications in the treatment of various dermatological infections; at a concentration of 2% its use is considered safe, with a low risk of irritation for the skin; the adverse events observed are occasional, the essential oil of tea tree is irritating only in high doses or if it is not stored correctly; in this case, allergic reactions due to oxidation products develop. The essential oil of Melaleuca alternifolia has proven effective in particular against Candida, in the treatment of seborrheic dermatitis, acne, in the presence of psoriasis or herpes.
I componenti dell’olio essenziale di melaleuca (Melaleuca alternifolia) agiscono prevalentemente causando alterazioni nella membrana dei microrganismi, provocando la lisi e la denaturazione delle proteine; à ̈ stata osservata anche un’azione antiossidante, importante nel contrastare i radicali liberi, che aumentano durante l’infiammazione, e un’azione nel favorire la riepitelizzazione; inoltre, l’impiego del fitocomplesso in toto à ̈ utile per sfruttare al massimo l’azione sinergica fra i componenti e ha il vantaggio di non alterare la flora batterica saprofita presente sulla cute e necessaria per mantenere l’equilibrio fisiologico. The components of the essential oil of tea tree (Melaleuca alternifolia) act mainly by causing alterations in the membrane of microorganisms, causing the lysis and denaturation of proteins; An antioxidant action was also observed, which is important in fighting free radicals, which increase during inflammation, and an action in favoring re-epithelialization; moreover, the use of the phytocomplex in its entirety is useful for making the most of the synergistic action between the components and has the advantage of not altering the saprophytic bacterial flora present on the skin and necessary to maintain physiological balance.
Il componente principale dell’olio di germe di grano (Triticum vulgare) à ̈ la vitamina E (presente essenzialmente come alfa-tocoferolo), nota per le sue proprietà antiossidanti e soprattutto per mantenere efficienti le reazioni di ossidoriduzione che inattivano i radicali liberi; i radicali liberi sono composti chimici altamente reattivi, che possono danneggiare molecole di importanza biologica e compromettere la funzionalità di diversi organi e tessuti, coinvolti nella fisiopatologia di molte patologie nell’uomo. The main component of wheat germ oil (Triticum vulgare) is vitamin E (essentially present as alpha-tocopherol), known for its antioxidant properties and above all for maintaining efficient redox reactions that inactivate free radicals; free radicals are highly reactive chemical compounds, which can damage molecules of biological importance and compromise the functionality of various organs and tissues, involved in the physiopathology of many pathologies in man.
Le formulazioni topiche a base di vitamina E trovano ampia applicazione in dermatologia, soprattutto nel trattamento della xerosi cutanea, associata o meno al prurito, inoltre diversi studi hanno evidenziato che la vitamina E à ̈ la principale sostanza antiossidante a livello delle strutture lipidiche; sulla cute la sua azione antiossidante si esplica a livello delle membrane cellulari, proteggendole dalle aggressioni dei radicali liberi e contrastando l’ossidazione degli acidi grassi polinsaturi, sia a livello delle strutture lipidiche che della matrice extracellulare. L’olio di germe di grano idrata e rigenera la cute, aumentando per esempio la sintesi di elastina e collagene. Topical formulations based on vitamin E find wide application in dermatology, especially in the treatment of cutaneous xerosis, associated or not with itching. Furthermore, several studies have shown that vitamin E is the main antioxidant substance at the level of lipid structures; on the skin, its antioxidant action is carried out at the level of cell membranes, protecting them from the aggression of free radicals and counteracting the oxidation of polyunsaturated fatty acids, both at the level of the lipid structures and of the extracellular matrix. Wheat germ oil moisturizes and regenerates the skin, for example by increasing the synthesis of elastin and collagen.
Le proprietà medicinali dell’elicriso sono note da molto tempo: contiene flavonoidi, nerolo, acido caffeico, proantocianidine, tannini e tra le proprietà spiccano quelle antinfiammatoria, antiallergica e antiedematosa. Viene impiegato nelle preparazioni per uso topico per il trattamento di diverse affezioni cutanee, come la psoriasi e gli eczemi, ha un’azione preventiva sugli eritemi e su alcune dermatiti e un’azione decongestionante e fotoprotettiva: à ̈ in grado di modificare quadri clinici diversi ma aventi un analogo stato patogenetico; il meccanismo d’azione coinvolge diverse sostanze: i composti sterolici e triterpenici presenti possono considerarsi pre-ormoni, trasformabili dall’organismo, in caso di stati carenziali, in ormoni cortico surrenali; recentemente à ̈ stata scoperta una serie di derivati inibitori che agiscono sulla cascata infiammatoria; altre sostanze, come le proantocianidine svolgono un’azione antiossidante. The medicinal properties of helichrysum have been known for a long time: it contains flavonoids, nerol, caffeic acid, proanthocyanidins, tannins and among its properties the anti-inflammatory, anti-allergic and anti-edematous properties stand out. It is used in topical preparations for the treatment of various skin diseases, such as psoriasis and eczema, has a preventive action on erythema and some dermatitis and a decongestant and photoprotective action: it is able to modify pictures different clinicians but having a similar pathogenetic state; the mechanism of action involves various substances: the sterol and triterpene compounds present can be considered pre-hormones, transformable by the organism, in case of deficiency states, into adrenal cortical hormones; a series of inhibitory derivatives which act on the inflammatory cascade have recently been discovered; other substances, such as proanthocyanidins, have an antioxidant action.
In conclusione, le composizioni dell’invenzione hanno evidenziato assenza di effetti collaterali o allergizzanti, efficacia nel trattamento di diverse affezioni dermatologiche, e una buona tollerabilità , e possono essere anche utili nel combattere le recidive, in quanto non inducono alterazioni della flora saprofita presente sulla cute né fenomeni di resistenza. In conclusion, the compositions of the invention have shown the absence of side or allergenic effects, efficacy in the treatment of various dermatological diseases, and a good tolerability, and can also be useful in combating relapses, as they do not induce alterations of the saprophytic flora present. on the skin or phenomena of resistance.
Le composizioni della presente invenzione potranno inoltre contenere altri componenti attivi, ad azione complementare o comunque utile ai fini dell’invenzione, quali ad esempio vitamina C, antiossidanti contro l’ossidazione dell’olio di melaleuca. The compositions of the present invention may also contain other active components, having a complementary action or in any case useful for the purposes of the invention, such as for example vitamin C, antioxidants against the oxidation of tea tree oil.
Le composizioni della presente invenzione potranno essere formulate in modo adatto alla somministrazione per via topica e saranno preparate secondo metodi convenzionali ben noti in tecnica farmaceutica, come quelli descritti in "Remington's Pharmaceutical Handbook", Mack Publishing Co., N.Y., USA, utilizzando eccipienti, diluenti, agenti di carica, antiagglomeranti accettabili per il loro uso finale. The compositions of the present invention can be formulated in a manner suitable for topical administration and will be prepared according to conventional methods well known in the pharmaceutical technique, such as those described in "Remington's Pharmaceutical Handbook", Mack Publishing Co., N.Y., USA, using excipients, diluents, bulking agents, anti-caking agents acceptable for their final use.
Esempi di formulazioni preferite secondo la presente invenzione sono gel, emulsioni (olio in acqua (o/w) e acqua in olio (w/o)), creme, pomate, spray, polveri, lozioni, schiume, fazzolettini, garze. Examples of preferred formulations according to the present invention are gels, emulsions (oil in water (o / w) and water in oil (w / o)), creams, ointments, sprays, powders, lotions, foams, tissues, gauze.
Si riportano di seguito alcuni esempi specifici di formulazioni dell’invenzione. Some specific examples of formulations of the invention are reported below.
Esempio 1 – Formulazione Detergente Example 1 - Detergent Formulation
La formulazione detergente, utile per detergere ad esempio la cute o i capelli, Ã ̈ costituita da (le percentuali si intendono in ml sul volume totale della formulazione): The cleansing formulation, useful for cleansing the skin or hair, for example, consists of (the percentages are in ml of the total volume of the formulation):
ƒ Melaleuca alternifolia (Melaleuca) olio 2% ƒ Melaleuca alternifolia (Melaleuca) oil 2%
ƒ Triticum vulgare (Germe di Grano) olio 5% ƒ Triticum vulgare (Wheat Germ) oil 5%
ƒ Helichrysum italicum (Elicriso) estratto 2% ƒ Helichrysum italicum (Helichrysum) extract 2%
Eccipienti: Excipients:
ƒ Acqua ƒ Water
ƒ Solfato di Laurato di Magnesio ƒ Magnesium Laurate Sulphate
ƒ PEG-40 olio di Ricino idrogenato ƒ PEG-40 hydrogenated castor oil
ƒ Polisorbato 80 ƒ Polysorbate 80
ƒ Propilenglicole ƒ Propylene glycol
ƒ Cocamidopropilbetaina ƒ Cocamidopropylbetaine
ƒ PEG-120 metilglucosio dioleato ƒ PEG-120 methylglucose dioleate
ƒ Sorbitolo ƒ Sorbitol
ƒ Sodio lauroilsarcosinato ƒ Sodium lauroylsarcosinate
ƒ Disodio laurato solfo succinato cloruro ƒ Disodium laurate sulfur succinate chloride
ƒ Sodio deidroacetato ƒ Sodium dehydroacetate
ƒ EDTA bisodico ƒ disodium EDTA
ƒ Sodio benzoato ƒ Sodium benzoate
ƒ Sodio salicilato ƒ Sodium salicylate
ƒ Acido citrico ƒ Citric acid
ƒ Limonene ƒ Limonene
Esempio 2 – Formulazione Crema Example 2 - Cream formulation
La formulazione in forma di crema, può essere utilizzata ad esempio sul corpo, sul viso, à ̈ costituita da (le percentuali si intendono in ml sul volume totale della formulazione): The formulation in the form of cream, can be used for example on the body, on the face, is made up of (the percentages are in ml of the total volume of the formulation):
ƒ Melaleuca alternifolia (Melaleuca) olio 2% ƒ Melaleuca alternifolia (Melaleuca) oil 2%
ƒ Triticum vulgare (Germe di Grano) olio 5% ƒ Triticum vulgare (Wheat Germ) oil 5%
ƒ Helichrysum italicum (Elicriso) estratto 5% Eccipienti: ƒ Helichrysum italicum (Helichrysum) extract 5% Excipients:
ƒ Acqua ƒ Water
ƒ Alcol cetilico ƒ Cetyl alcohol
Di-C12-C13alchil maleato Di-C12-C13alkyl maleate
Propilenglicole Propylene glycol
Cetearil isononanoato Cetearyl isononanoate
Decil oleato Decyl oleate
Potassio palmitoil idrolizzato di proteine di grano Gliceril stearato Potassium palmitoyl hydrolyzate of wheat proteins Glyceryl stearate
Alcol cetearilico Cetearyl alcohol
Gomma xantano Xanthan gum
Dimeticone Dimethicone
EDTA bisodico Disodium EDTA
Acido sorbico Sorbic acid
Acido butilottanoico Butyloctanoic acid
Sodio deidroacetato Sodium dehydroacetate
Insaponificabile da Olio di Oliva (Olea Europea) Tocoferil acetato Unsaponifiable from Olive Oil (Olea Europea) Tocopheryl acetate
Limonene Limonene
Linaiolo Linaiolo
Claims (8)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI2010A000840A IT1400093B1 (en) | 2010-05-12 | 2010-05-12 | TOPICAL PHYTOTHERAPY COMPOSITIONS |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITMI2010A000840A IT1400093B1 (en) | 2010-05-12 | 2010-05-12 | TOPICAL PHYTOTHERAPY COMPOSITIONS |
Publications (2)
Publication Number | Publication Date |
---|---|
ITMI20100840A1 true ITMI20100840A1 (en) | 2011-11-13 |
IT1400093B1 IT1400093B1 (en) | 2013-05-17 |
Family
ID=43365265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ITMI2010A000840A IT1400093B1 (en) | 2010-05-12 | 2010-05-12 | TOPICAL PHYTOTHERAPY COMPOSITIONS |
Country Status (1)
Country | Link |
---|---|
IT (1) | IT1400093B1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6576269B1 (en) * | 2001-09-06 | 2003-06-10 | Alexander Y. Korneyev | Treating open skin lesions using extract of sea buckthorn |
GB2440601A (en) * | 2006-08-05 | 2008-02-06 | Julie Ann Mitchell | Cream formulations |
FR2915095A1 (en) * | 2007-04-17 | 2008-10-24 | N Diaye Yacine Isabelle Moniqu | Cosmetic composition, useful e.g. for face and body, to fight against skin aging while protecting from weather and pollution, comprises compounds with natural and non-toxic active ingredients |
-
2010
- 2010-05-12 IT ITMI2010A000840A patent/IT1400093B1/en active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6576269B1 (en) * | 2001-09-06 | 2003-06-10 | Alexander Y. Korneyev | Treating open skin lesions using extract of sea buckthorn |
GB2440601A (en) * | 2006-08-05 | 2008-02-06 | Julie Ann Mitchell | Cream formulations |
FR2915095A1 (en) * | 2007-04-17 | 2008-10-24 | N Diaye Yacine Isabelle Moniqu | Cosmetic composition, useful e.g. for face and body, to fight against skin aging while protecting from weather and pollution, comprises compounds with natural and non-toxic active ingredients |
Also Published As
Publication number | Publication date |
---|---|
IT1400093B1 (en) | 2013-05-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11534470B2 (en) | Topical treatments incorporating Cannabis sp. derived botanical drug product | |
US11571373B2 (en) | Skin care preparations for babies | |
US9468597B1 (en) | Stabilized L-ascorbic acid skin serum | |
DE202005007603U1 (en) | Composition for oral or topical administration, e.g. as a dietary supplement or dietetic food, shower gel, body lotion, cream or care concentrate, comprises argan oil and nigella oil | |
KR102142311B1 (en) | Skin external composition comprising tangeretin | |
EP2745841B1 (en) | Compositions for the treatment of dermatological conditions, disorders or diseases | |
US20150086522A1 (en) | Formulation containing herb infused aloe | |
US20210322338A1 (en) | Compositions comprising cbd for treating dermatological conditions | |
Han | Development of an effective formulation for an acne treatment cream with Ocimum basilicum using invasomes | |
WO2022147470A1 (en) | Improved topical cannabinoid compositions and methods of making and using same | |
CA2798121C (en) | Topical composition and use thereof for the prophylaxis and the treatment of defects connected to inflammatory dermopathies | |
US10588979B1 (en) | Cannabinoid and terpene-infused topical cream | |
KR20110030187A (en) | (a cosmetic composition for skin miosture containing mixing extract of sparassis crispa, agaricus blazeii and polyporus umbellatus | |
EP3108877A1 (en) | Topical composition comprising natural ingredients for bruising or hematoma healing on skin and use thereof | |
ITMI20100840A1 (en) | TOPICAL PHYTOTHERAPY COMPOSITIONS | |
Ruiz et al. | Skin creams made with olive oil | |
ITMI20072063A1 (en) | MULTIFUNCTIONAL COSMETIC COMPOSITIONS FOR THE CARE AND THE WELL-BEING OF THE SKIN | |
US20170239169A1 (en) | Illuminating and Pore Refining Complexes | |
Fibrich et al. | Nanotechnology and Anti-Ageing Skin Care | |
EP3150188A1 (en) | A topical composition of dexpanthenol for the treatment of diaper rash | |
Care | 21 Nanotechnology and | |
EP4274540A1 (en) | Stable efficient cosmetic preparations | |
JP6175280B2 (en) | Composition for improving pores | |
BR102021004150A2 (en) | METHOD FOR PRODUCTION OF NANO CREAM AND LIPOSOMAR MICROSSYSTEMS CONTAINING POLAR EXTRACT OF ERYTHROXYLUM RIMOSUM | |
KR20150050981A (en) | Cosmetic composition and external composition comprising steroidal lactones for anti-inflammatory |